Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Pancreatic Neoplasms 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Breast Cancer Metastatic 1

Interventions

Paclitaxel 30Carboplatin 24Cisplatin 11Topotecan 8liposomal doxorubicin 6Hyperthermic Intraperitoneal Chemotherapy 6mirvetuximab soravtansine 5Cyclophosphamide 5Drug Therapy 4Chemotherapy, Adjuvant 4Bevacizumab 4rucaparib 3Peripheral Blood Stem Cell Transplantation 3Neoadjuvant Therapy 3Doxorubicin 3Docetaxel 3CP protocol 3olaparib 2liposomal amphotericin B 2Surgical Procedures, Operative 2Letrozole 2Gemcitabine 2trebananib 1trastuzumab deruxtecan 1phenoxodiol 1pembrolizumab 1oregovomab 1niraparib 1fluzoparib 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Ovarian Epithelial × fluzoparib × Clear all
NCT06539091 2024-08-06

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

Anhui Provincial Hospital

Phase 3 Not yet recruiting
51 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡